The company announced Q4 results after market hours on Tuesday, 7 May 2013.
Meanwhile, the S&P BSE Sensex was up 6.45 points or 0.03% at 19,895.40.
On BSE, 19,110 shares were traded in the counter as against average daily volume of 10,056 shares in the past one quarter.
The stock hit a high of Rs 178 and a low of Rs 162.60 so far during the day. The stock had hit a 52-week low of Rs 154 on 6 August 2012. The stock had hit a 52-week high of Rs 248.25 on 10 December 2012.
The stock had underperformed the market over the past one month till 7 May 2013, falling 0.34% compared with the Sensex's 7.8% surge. The scrip had also underperformed the market in past one quarter, sliding 13.02% as against Sensex's 1.58% rise.
The small-cap company has equity capital of Rs 15.93 crore. Face value per share is Re 1.
Jubilant Life Sciences' consolidated profit after tax (PAT), excluding extraordinary items, declined 20.48% to Rs 66 crore in Q4 March 2013 over Q4 March 2012. Income from operations rose 18% to Rs 1392 crore in Q4 March 2013 over Q4 March 2012. Earnings before interest, taxation, depreciation and amortization (EBITDA) stood at Rs 244 crore in Q4 March 2013. EBITDA margin stood at 17.5% in Q4 March 2013.
Jubilant Life Sciences' consolidated (PAT), excluding extraordinary items, rose 5% to Rs 382 crore in FY 2013 over FY 2012. Income from operations rose 21% to Rs 5161 crore in FY 2013 over FY 2012. EBITDA grew 18% to Rs 1055 crore year-on-year (YoY) with EBITDA margin at 20.4% in FY 2013.
Jubilant Life Sciences said that the company's international revenues accounted for 74% of the revenue mix at Rs 3831 crore with regulated markets revenue at an all time high of Rs 3194 crore in FY 2013. Revenue from North America stood at Rs 2132 crore, higher by 27% YoY, with a share of 41% in the overall revenues, Jubilant Life Sciences said. Revenues from Europe and Japan stood at Rs 1061 crore, gaining 32% with contribution of 21% to the revenue mix. Domestic revenues were at Rs 1330 crore, up 5% YoY with 26% share to the revenue mix. Revenues from ROW including China stood at Rs 637 croree, up 22% with a 12% share to the revenue mix, the company said in a statement.
With regard to future business outlook, Jubilant Life Sciences said that the growth momentum in the company's revenue and EBITDA is expected to continue and that the outlook remains robust. In the pharmaceuticals segment, the strategy of new product launches and geographic expansion will continue to drive growth while the key driver in the life science ingredients segment will be higher capacity utilisation in the nutrition ingredients and crop science intermediates supported by backward integration of Pyridine, the company said in a statement.
Jubilant Life Sciences' board of directors at a meeting held on Tuesday, 7 May 2013, accorded its approval to constitute a committee to explore options and opportunities to raise debt for the company, including by way of issue of foreign currency bonds and/or non-convertible debentures, or by any one or more or a combination of the above or otherwise, to be denominated in Indian rupees or foreign currency, as the case may be, to various eligible investors in or outside India, whether by way of a public offering or by way of a private placement, in the best interests of the company and all its stakeholders, up to an amount not exceeding $250 million for prepayment of the existing debt and other general corporate purposes without increasing the overall net debt levels of the company.
Jubilant Life Sciences' board also recommended a dividend of Rs 3 per share for FY 2013.
Jubilant Life Sciences is a global pharmaceutical and life sciences company engaged in manufacture and supply of APIs, generics, specialty pharmaceuticals and life science ingredients. It also provides services in contract manufacturing and drug discovery and development.
Powered by Capital Market - Live News
